Literature DB >> 27802157

Gut microbiome and liver diseases.

Herbert Tilg1, Patrice D Cani2, Emeran A Mayer3.   

Abstract

The gut microbiota has recently evolved as a new important player in the pathophysiology of many intestinal and extraintestinal diseases. The liver is the organ which is in closest contact with the intestinal tract, and is exposed to a substantial amount of bacterial components and metabolites. Various liver disorders such as alcoholic liver disease, non-alcoholic liver disease and primary sclerosing cholangitis have been associated with an altered microbiome. This dysbiosis may influence the degree of hepatic steatosis, inflammation and fibrosis through multiple interactions with the host's immune system and other cell types. Whereas few results from clinical metagenomic studies in liver disease are available, evidence is accumulating that in liver cirrhosis an oral microbiome is overrepresented in the lower intestinal tract, potentially contributing to disease process and severity. A major role for the gut microbiota in liver disorders is also supported by the accumulating evidence that several complications of severe liver disease such as hepatic encephalopathy are efficiently treated by various prebiotics, probiotics and antibiotics. A better understanding of the gut microbiota and its components in liver diseases might provide a more complete picture of these complex disorders and also form the basis for novel therapies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  ALCOHOLIC LIVER DISEASE; HEPATIC ENCEPHALOPATHY; LIVER CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS

Mesh:

Substances:

Year:  2016        PMID: 27802157     DOI: 10.1136/gutjnl-2016-312729

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  126 in total

1.  Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health.

Authors:  Baolei Jia; Dongbin Park; Yoonsoo Hahn; Che Ok Jeon
Journal:  Gut Microbes       Date:  2020-04-24

2.  Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Gut Microbes       Date:  2020-03-13

Review 3.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.

Authors:  Natalia Vallianou; Theodora Stratigou; Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-09

4.  Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.

Authors:  Shogo Takahashi; Yuhuan Luo; Suman Ranjit; Cen Xie; Andrew E Libby; David J Orlicky; Alexander Dvornikov; Xiaoxin X Wang; Komuraiah Myakala; Bryce A Jones; Kanchan Bhasin; Dong Wang; James L McManaman; Kristopher W Krausz; Enrico Gratton; Diana Ir; Charles E Robertson; Daniel N Frank; Frank J Gonzalez; Moshe Levi
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

5.  Gut microbiome-immune crosstalk affects progression of cancer.

Authors:  Herbert Tilg; Andreas Schmiderer; Angela Djanani
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-19

Review 6.  The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Authors:  Marco Sanduzzi Zamparelli; Alba Rocco; Debora Compare; Gerardo Nardone
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

7.  Effects of Wnt-1 blockade in DEN-induced hepatocellular adenomas of mice.

Authors:  Argyrios Sklavos; Theofilos Poutahidis; Alexander Giakoustidis; Kali Makedou; Katerina Angelopoulou; Alexander Hardas; Paola Andreani; Argyro Zacharioudaki; George Saridis; Thomas Goulopoulos; Kalliopi Tsarea; Maria Karamperi; Vassilios Papadopoulos; Vassilios Papanikolaou; Apostolos Papalois; Stavros Iliadis; Satvinder Mudan; Daniel Azoulay; Dimitrios Giakoustidis
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

8.  A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota.

Authors:  Moustafa T Gabr; David Machalz; Szymon Pach; Gerhard Wolber
Journal:  RSC Med Chem       Date:  2020-08-28

Review 9.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

10.  Liver Injury Impaired 25-Hydroxylation of Vitamin D Suppresses Intestinal Paneth Cell defensins, leading to Gut Dysbiosis and Liver Fibrogenesis.

Authors:  Pengfei Wu; Ruofei Zhang; Mei Luo; Tianci Zhang; Lisha Pan; Siya Xu; Liwei Pan; Feng Ren; Cheng Ji; Richard Hu; Mazen Noureddin; Stephen J Pandol; Yuan-Ping Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-10-21       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.